Kelun pharmaceutical "moxifloxacin hydrochloride and sodium chloride injection" obtained the drug registration approval

According to the announcement of Sichuan Kelun Pharmaceutical Co., Ltd on May 5, the company recently obtained the approval document for drug registration of the chemical "moxifloxacin hydrochloride and sodium chloride injection" approved and issued by the State Drug Administration Moxifloxacin hydrochloride and sodium chloride injection are mainly used to treat adult upper and lower respiratory tract infections, skin and soft tissue infections, complex abdominal infections, including mixed bacterial infections Moxifloxacin is the fourth generation of quinolones Together with levofloxacin (the third generation) and Jimmy floxacin (the fourth generation), moxifloxacin is known as "respiratory quinolones", especially for Streptococcus pneumoniae with severe drug resistance Domestic authoritative guidelines, such as guidelines for clinical application of antibiotics (2015), guidelines for diagnosis and treatment of adult community acquired pneumonia (2016), recommend respiratory quinolone as the initial empirical treatment drug for community acquired pneumonia; ksid clinical guidelines: antibiotic treatment for community acquired skin and soft tissue infection (2017), recommend moxifloxacin for animal or human bites Causes skin and soft tissue infections This data comes from "drug intelligence data network"